Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
This marks the second indication for which gumokimab has gained NDA review acceptance
This marks the second indication for which gumokimab has gained NDA review acceptance
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Subscribe To Our Newsletter & Stay Updated